Therefore, we designed a strategy to engineer a newly oncolytic vector AdV-D24-ICOSL-CD40L and investigated its anti-tumor activity in combination with anti PD-1 in in vitro and in vivo immunocompetent mouse model engrafted with murine B16V melanoma cells. This evidence concerns the gene CD40LG and melanoma.